EGFR and renal carcinoma: For example, the EGFR kinase inhibitors gefitinib and erlotinib for non-small cell lung cancer patients; the EGFR/ERBB2 inhibitor lapatinib for ERBB2-positive breast cancer patients, and the VEGFR kinase inhibitor sorafenib for patients with renal cancer [118].